EDAP's Long Term Academic HIFU Partner INSERM LabTAU Designated Center of Excellence by the Focused Ultrasound Foundation
March 08 2017 - 10:52AM
LYON, France, March 8, 2017 -- EDAP TMS SA (Nasdaq:
EDAP), the global leader in therapeutic ultrasound, today announced
that the prestigious Focused Ultrasound Foundation, based in
Charlottesville, VA, designated long-term academic French partner
INSERM LabTAU a Center of Excellence.
EDAP and INSERM Laboratory of Therapeutic Applications of
Ultrasound (LabTAU), in conjunction with the University Hospital
Edouard Herriot in Lyon, have been collaborating closely for the
past 27 years in the development and use of therapeutic ultrasound
in the treatment of kidney stones and localized prostate cancer.
These strategic interfaces resulted in the successful marketing of
Sonolith®, Ablatherm® Robotic-HIFU and Focal One®
worldwide. So far, more than 45,000 prostate cancer patients have
been treated using our HIFU technology. EDAP and INSERM LabTAU are
currently pursuing on-going development projects using HIFU for
therapeutic applications beyond prostate cancer.
Dr. Cyril Lafon, Ph.D., Director of LabTAU, commented: "INSERM
LabTAU and EDAP privileged partnership is a valuable example of a
fruitful and successful cooperation between academic scientists and
a medical device company. Our expertise and advancements are
complementary thus accelerating the availability of such
non-invasive technology as HIFU to patients."
"LabTAU at INSERM is a pioneering site for research and
development in focused ultrasound. They have a long history of
establishing how focused ultrasound interacts with tissue, and they
use that information to develop innovative clinical applications,"
says Foundation Chairman Neal F. Kassell, MD. "Their laboratory
research has resulted in a number of commercially available
products -- including those used for the first focused ultrasound
treatment for patients with prostate cancer."
Marc Oczachowski, EDAP TMS Chief Executive Officer, concluded:
"We are very enthusiastic and proud of the nomination of our
privileged partner INSERM LabTAU as Center of Excellence by the
prestigious Focused Ultrasound Foundation. It is a recognition of
INSERM's highly qualified research work on therapeutic ultrasound.
The designation validates our successful collaboration in
developing HIFU and ensuring that our co-advancements benefit
patients. We at EDAP remain dedicated to making HIFU a standard of
care in the treatment of particular types of tumors."
For more information on the designation of INSERM LabTAU as
Center of Excellence, please refer to the Focused Ultrasound
release: https://www.fusfoundation.org/news/1882-new-center-of-excellence-focuses-on-collaborations-and-education.
About EDAP TMS SAEDAP TMS SA markets today Ablatherm® for
high-intensity focused ultrasound (HIFU) for prostate tissue
ablation in the U.S. and for treatment of localized
prostate cancer in the rest of the world. HIFU treatment is shown
to be a minimally invasive and effective option for prostatic
tissue ablation with a low occurrence of side effects. Ablatherm is
generally recommended for patients with localized prostate cancer
(stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Ablatherm is approved for commercial distribution in
Europe and other countries including Mexico
and Canada, and has received 510(k) clearance by the U.S.
FDA. The Company also markets an innovative robot-assisted HIFU
device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com,
and http://www.hifu-planet.com.
About INSERM LabTAU
The laboratory LabTAU for Laboratory of Therapeutic Applications
of Ultrasound (Claude Bernard Lyon 1 University and INSERM Unit
1032), under the direction of Cyril Lafon, is specialized in the
development of non-invasive or minimally invasive therapeutic
applications of image-guided ultrasound, by combining experimental
and theoretical research for which very few teams, even
international, possess the required know-how. Since January 1,
2005, the laboratory has produced 198 publications
in referred journals and 190 communications, including 22
invited communications. Technological or methodological
expertise of the team and its partners covers the entire range of
investigations from the bench to the bedside. The research on
ultrasound therapy conducted in LabTAU is widely regarded as being
at the forefront of worldwide developments in this field leading to
international activity by means of several actions: reception of
foreign researchers, European actions, bilateral collaboration
contracts, thesis co-supervision. For more information on INSERM
LabTAU,
please visit: http://labtau.univ-lyon1.fr/.
About The Focused Ultrasound Foundation
The Focused Ultrasound Foundation (FUSF) is a non-profit
organization based in Charlottesville, Virginia, United States,
dedicated to accelerating the development and adoption of focused
ultrasound. Its main areas of involvement and support are research,
collaboration, education and advocacy. In 2009, the
Foundation created the Centers of Excellence program which brings
together the best people and technical resources at luminary sites
to showcase the technology and serve as hubs for collaboration. For
more information on the Foundation, please
visit https://www.fusfoundation.org.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also
may include, but are not limited to, those described in
the Company's filings with the Securities and Exchange Commission
and in particular, in the sections "Cautionary Statement on
Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F.
Investor Contact
CG CAPITALRich
Cockrell877.889.1972investorrelations@cg.capital
Company Contact
Blandine ConfortInvestor Relations / Legal Affairs EDAP TMS
SA+33 4 72 15 31 50bconfort@edap-tms.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Apr 2023 to Apr 2024